All In MedTech

Device Trial Radar · NCT07192159

Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference

Evaluation of a Quantitative Ultrasound Model for Liver Fat Quantification in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Prospective Study Using MRI-PDFF as Reference, With Interplatform Reproducibility

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Jun 24, 2025

Primary completion

Apr 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Northeastern Ohio Radiology Research and Education Fund
First posted
Sep 25, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study will compare the diagnostic accuracy of quantitative ultrasound imaging against MRI-PDFF as the reference standard. ==\> V 4.0: Prospective multicenter study evaluating the correlation between Samsung Medison quantitative ultrasound (DeepUSFF) and MRI-PDFF in patients with MASLD across two ultrasound platforms (RS85 and R20). Total target enrollment 182 participants in two parallel device arms: RS85 arm (n=62; SNUH 31 + US site 31) and R20 arm (n=120; SNUH). Within the R20 arm, a paired-device substudy (n=60) evaluates interplatform reproducibility between R20 and RS85. Secondary objectives include intra- and inter-observer agreement of DeepUSFF on each platform.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Hepatic Steatosis
  • Liver Disease Parenchymal

Interventions

  • Quantitative ultrasound (DeepUSFF)Device

    \*\*Novel Quantitative Ultrasound Technology Assessment\*\* This study evaluates Samsung Medison's proprietary DeepUSFF (Deep Learning-based Ultrasound Fat Fraction) technology, a next-generation quantitative ultrasound method for liver fat assessment that differs from conventional ultrasound approaches in several key aspects: advanced RF data analysis, proprietary technology, standardized protocol, direct MRI-PDFF correlation, specific MSALD poopulation and multicenter design.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation between Ultrasound Fat Fraction and MRI-PDFFTime frame: At enrollment (single time point assessment)
  2. Correlation between Ultrasound Fat Fraction and MRI-PDFFTime frame: At enrollment (single time point assessment)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • southwoods imaging (Northeastern Ohio Radiology Research and Education Fund )

    Boardman, Ohio

  • Seoul National University Hospital

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.